Clinical Research Directory

Inclusion Criteria: * Male or female aged ≥18 years at the time of signing informed consent form * Measurable disease per RECIST 1.1 * Histologically- or cytologically-diagnosed, locally advanced unresectable or metastatic solid tumor. Progressed or recurred after previously having received approved standard of care agents that are approved and available in their local geography. * ECOG Performance status of 0 or 1 * Life expectancy of at least 3 months * Adequate organ and marrow function * Contraception during study participation, as applicable Exclusion Criteria: * Has received systemic small molecule therapy or radiation therapy within 28 days prior to the first dose. * Treatment with biologic agents including anti-PD-1 or PD-L1 antibodies for less than 6 weeks or 5 half-lives, whichever is shorter, prior to first dose. * Received any investigational agent less than 28 days or 5 half-lives, whichever is shorter, prior to the first dose. * Treatment with another IL-18 therapy. * Received systemic immunosuppressive agents greater than the equivalent of prednisone 10mg daily within 14 days of the study, though inhaled, intranasal, topical or intra-articular corticosteroids are allowed. * Certain clinically significant intercurrent disease. * Primary immune deficiency. * Active untreated brain or spine metastasis or leptomeningeal metastases. * Known HIV seroposivitiy, although patients treated for HIV with no detectable viral load for at least 1 month while on a stable regimen of agents are permitted. * Active hepatitis A or acute or chroming hepatitis B or C infection. * Received a live virus vaccine within 30 days of enrollment or a COVD vaccine within 14 days.